Ed Miseta

Ed Miseta



Ed Miseta is chief editor for the website Clinical Leader, executive editor for Life Science Leader magazine, conference chair for Clinical Leader Forum, and host of Clinical Leader Live. Ed studied Business Economics at The Pennsylvania State University and also holds a Master’s degree in Business Administration. Ed has been a writer for more than 12 years and has been covering clinical research since January 2013. Ed spent 10 years in banking and investments and also taught economics at Penn State for 8 years. In his current position, Ed interviews clinical executives from pharmaceutical and biotech companies and shares their insights with readers. His primary focus is on best practices, challenges faced and overcome, clinical trends, partnering, and implementing new technologies. He has also moderated numerous speaker panels at industry conferences and trade shows.

ARTICLES BY ED MISETA

  • How COVID-19 Will Change Clinical Trials And End The Patient Recruitment Challenge

    Clinical technologies are evolving and promise to change how studies are conducted. Still, change takes time. Most companies do not rush out to embrace every new technology that comes along. The COVID-19 pandemic may be changing that.

  • New Report Focuses On Clinical Trial Disruption And The Impact On IRT

    New advances in technology, along with the COVID-19 pandemic, are contributing to the ongoing disruption in the clinical trial space. Other factors playing into the disruption are emerging biopharma companies, decreasing ROI, and shifts in R&D focus. A new research report finds the disruption has resulted in demand for significant changes in IRT systems.

  • Rare Disease Trials Require Interactions With KOLs, Patients, & Regulators

    Anyone working in the orphan or rare disease space knows the lack of a natural history for a disease is one of the greatest challenges a company might face. The same is true for Minoryx Therapeutics. According to CEO Marc Martinell, the lack of a natural history means companies do not have the information necessary to determine how clinical trials should be designed. 

  • Different CROs For Different Purposes – One Biotech’s Selection Process

    Morphogenesis has produced a cancer treatment that is injected directly into a tumor. When it came time to find CRO partners to navigate the clinical trial process, the company conducted thorough searches and selected partners based on their needs in a given situation. 

  • COVID Pandemic Hastens Search For New Technology And CRO Partner

    As the COVID-19 pandemic began to rage, Mateon Therapeutics was seeking a tool to assist with preclinical development. The crisis meant many patients were suddenly unable to visit clinics. Almost overnight the search for a preclinical development tool was suddenly a high priority.

  • Online Recruitment & A Virtual Study Net 4,000 Participants For MAGENTA Trial

    Stand Up To Cancer (SU2C) has been around for more than 10 years. The organization was founded to promote collaborative and innovative cancer research by bringing together the best and brightest minds in the industry. It's recent MAGENTA study recruited nearly 4,000 patients by using online tools and a virtual approach.

  • Why Is Antibiotic Development In The U.S. Disappearing?

    Today, 95 percent of antibiotics in development are being studied by smaller biotechs, including Paratek Pharmaceuticals. Today, the company is on a strong trajectory, but its ups and downs show why antibiotic companies fail and few new antibiotics reach patients.

  • Cure Rare Disease Wants To Disrupt The Clinical Trial Paradigm

    Cure Rare Disease is a nonprofit biotech. Rich Horgan, founder and president of the organization, says the idea behind the venture was to build a business that could investigate new ways to develop therapeutics. Horgan felt organizing as a nonprofit would allow the company to take risks that a traditional venture capital group could not.

  • How TissueTech Managed Growth, Virtual Trials, And Survived COVID-19

    Since its inception in 1997, TissueTech has been a pioneer in the clinical application of human birth tissues. In July 2020 the company announced the initiation of the first of two Phase 3 clinical trials. To complete those trials, the company knew it had to grow its internal capabilities. It did so by investing heavily in the expansion of its clinical and manufacturing programs.

  • Will Pharma Sustain Improved Reputation and Trust Beyond COVID-19?

    Pharma’s reputation has been battered in recent years, and Americans have never had a lower view of their prescription providers. Unfortunately, this is not simply an image issue. This viewpoint most certainly contributes to the challenge pharma companies face in recruiting participants into their clinical studies. While the industry had seemed unable to shake its negative image, there is now reason to believe the attitude of the public is shifting. The main reason for the turnaround is, surprisingly, COVID-19.